UNSPSC 51282935: Oxolinic acid

This classification denotes a quinolone antibiotic with the molecular formula C13H11NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0A22B22FT, chemically known as 1,3-dioxolo(4,5-g)quinoline-7-carboxylic acid, 5-ethyl-5,8-dihydro-8-oxo- but generally known as oxolinic acid, which bears US NIH Compound Identifier 4628. European Medicines Agency schedules Oxolinic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09548MIG. The term OXOLINIC ACID is an International Non-Proprietary Name.

UNSPSC 51282935 Oxolinic acid is a Commodity code that shows minimal relevant recent state and local procurement activity. The two opportunities tagged under this code involve pharmaceutical procurement — one awarded contract for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin) and one open solicitation for Naloxone and drug deactivation systems — neither of which involves oxolinic acid directly. The code itself nominally covers a specific antimicrobial pharmaceutical ingredient, but state and local governments appear to be procuring finished pharmaceutical products and medical supplies rather than raw chemical compounds or active pharmaceutical ingredients at the commodity level. The issuing bodies in the recent record are the Illinois Department of Public Health (state agency) and Seminole County, Florida (county health authority), both sourcing through standardized procurement channels including cooperative purchasing consortia (MMCAP) and competitive IFB processes.

Recent opportunities show activity in Illinois and Florida only. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract to Chartwell Rx LLC on August 28, 2026 through the MMCAP Infuse consortium for a 12-month initial term with two renewal options; this was a completed award under solicitation number 26482DPHPREPDB53392, not an open solicitation. Seminole County issued an IFB (number IFB60459723LAS) on June 30, 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, due by July 26, 2023 (note: the due date appears inconsistent with the posting date and may reflect a data anomaly in the source). The gap between the code's nominal scope and actual procurement activity, combined with the limited geographic representation and the absence of active open solicitations under this code, suggests low current pursuit value for vendors supplying oxolinic acid specifically.